KaloBios, battered by a string of clinical failures, is planning to soldier on with its thinning pipeline, cutting 61% of its workforce to conserve cash.
The South San Francisco biotech is laying off 17 workers and regrouping around a once-failed antibody that it now believes has a future in leukemia. The treatment, lenzilumab, failed a Phase II trial in severe asthma last year, leading ex-partner Sanofi to pull the plug on a deal worth up to $290 million. But KaloBios sees hope that the antibody’s target could play a role in the rare chronic myelomonocytic leukemia and is now plotting to start a Phase I trial in the fourth quarter.
The company’s most recent failure saw an antibody called KB001-A miss the mark in a Phase II study on a bacterial infection related to cystic fibrosis, results that were disclosed in January and quickly followed by a 20% headcount reduction and the departure of CEO David Pritchard.
Turning its full attention to lenzilumab’s leukemia program, KaloBios said it’s pausing enrollment in a Phase II study for the blood cancer therapy KB004. At the same time, KaloBios is looking into “strategic alternatives,” which would include the unlikely outcome of finding a company to buy it outright.
“While this decision was extremely difficult, aligning and managing our limited resources to maximize the opportunity for continued development of lenzilumab is our most important priority,” KaloBios Chief Financial Officer and interim CEO Herb Cross said in a statement. “I would like to sincerely thank all of our departing employees and recognize their important and valued contributions to KaloBios.”
The news sent KaloBios’ already decimated shares down about 30% on Thursday night, as investors reacted to the company’s decision to stay in business and not simply return what cash it has to shareholders.
Source: Fierce Biotech
Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.
Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.
Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.